Advertisement

Topics

Latest Biotechnology, Pharmaceutical and Healthcare News from European Medicines Agency

11:44 EST 14th December 2018 | BioPortfolio

Here are the most relevant search results for "European Medicines Agency" found in our extensive news archives from over 250 global news sources.

More Information about European Medicines Agency on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about European Medicines Agency for you to read. Along with our medical data and news we also list European Medicines Agency Clinical Trials, which are updated daily. BioPortfolio also has a large database of European Medicines Agency Companies for you to search.

Showing News Articles 1–25 of 5,000+ from European Medicines Agency

Wednesday 12th December 2018

Human medicines European public assessment report (EPAR): Exondys, eteplirsen, Muscular Dystrophy, Duchenne, Date of refusal: 20/09/2018, Status: Refused

Human medicines European public assessment report (EPAR): Exondys, eteplirsen, Muscular Dystrophy, Duchenne, Date of refusal: 20/09/2018, Status: Refused

Monday 26th November 2018

Human medicines European public assessment report (EPAR): Rxulti, brexpiprazole, Schizophrenia, Date of authorisation: 26/07/2018, Status: Authorised

Human medicines European public assessment report (EPAR): Rxulti, brexpiprazole, Schizophrenia, Date of authorisation: 26/07/2018, Status: Authorised

Human medicines European public assessment report (EPAR): Alunbrig, brigatinib, Carcinoma, Non-Small-Cell Lung, Date of authorisation: 22/11/2018, Status: Authorised

Human medicines European public assessment report (EPAR): Alunbrig, brigatinib, Carcinoma, Non-Small-Cell Lung, Date of authorisation: 22/11/2018, Status: Authorised

Thursday 22nd November 2018

Human medicines European public assessment report (EPAR): Symkevi, tezacaftor / ivacaftor, Cystic Fibrosis, Date of authorisation: 31/10/2018, Status: Authorised

Human medicines European public assessment report (EPAR): Symkevi, tezacaftor / ivacaftor, Cystic Fibrosis, Date of authorisation: 31/10/2018, Status: Authorised

Friday 16th November 2018

Summary of opinion: Blincyto,blinatumomab, 15/11/2018, Positive

Summary of opinion: Yervoy,ipilimumab, 15/11/2018, Positive

Summary of opinion: Ravicti, glycerol phenylbutyrate, 15/11/2018, Positive

Summary of opinion: Opdivo,nivolumab, 15/11/2018, Positive

Summary of opinion: Silodosin Recordati,silodosin, 15/11/2018, Positive

Summary of opinion: Orkambi,lumacaftor / ivacaftor, 15/11/2018, Positive

Summary of opinion: Macimorelin Aeterna Zentaris,macimorelin, 15/11/2018, Positive

Summary of opinion: MabThera,rituximab, 15/11/2018, Positive

Summary of opinion: Kisqali,ribociclib, 15/11/2018, Positive

Summary of opinion: Erleada,apalutamide, 15/11/2018, Positive

Friday 9th November 2018

Summary of opinion: Syvazul BTV,bluetongue virus vaccine, serotype 1 (inactivated) / bluetongue virus vaccine, serotype 4 (inactivated) / bluetongue virus vaccine, serotype 8 (inactivated) / bluetongue virus vaccine, serotype 4 (inactivated) / bluetongue

Summary of opinion: Isemid,Torasemide, 08/11/2018, Positive

Summary of opinion: Aftovaxpur DOE,Foot-and-mouth disease vaccine (inactivated) (multistrain: 1-3 strains out of set of 8), 08/11/2018, Positive

Tuesday 30th October 2018

Human medicines European public assessment report (EPAR): Imfinzi, durvalumab, Carcinoma, Non-Small-Cell Lung, Date of authorisation: 20/09/2018, Status: Authorised

Human medicines European public assessment report (EPAR): Imfinzi, durvalumab, Carcinoma, Non-Small-Cell Lung, Date of authorisation: 20/09/2018, Status: Authorised

Friday 26th October 2018

Human medicines European public assessment report (EPAR): Pelgraz, pegfilgrastim, Neutropenia, Date of authorisation: 20/09/2018, Status: Authorised

Human medicines European public assessment report (EPAR): Pelgraz, pegfilgrastim, Neutropenia, Date of authorisation: 20/09/2018, Status: Authorised

Tuesday 23rd October 2018

Summary of opinion: Flucelvax Tetra,influenza vaccine surface antigen inactivated prepared in cell cultures, 18/10/2018, Positive

Summary of opinion: Dengvaxia,dengue tetravalent vaccine (live, attenuated), 18/10/2018, Positive

Saturday 20th October 2018

Summary of opinion: Ogivri,trastuzumab, 18/10/2018, Positive

Summary of opinion: NovoSeven,eptacog alfa (activated), 18/10/2018, Positive

Summary of opinion: Namuscla,mexiletine hcl, 19/10/2018, Positive

Summary of opinion: Keytruda,pembrolizumab, 18/10/2018, Positive


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks